Zafgen, Inc. Announces Participation at XSITE 2009 Read more about Zafgen, Inc. Announces Participation at XSITE 2009 Zafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009 Read more about Zafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009 Zafgen, Inc. to Present at Upcoming Conferences Read more about Zafgen, Inc. to Present at Upcoming Conferences Zafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting Read more about Zafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity Read more about Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity Zafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference Read more about Zafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference Zafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting Read more about Zafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting Zafgen Secures $33 Million Series C Financing Read more about Zafgen Secures $33 Million Series C Financing Zafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer Read more about Zafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer Zafgen to Present at The Obesity Society 29th Annual Scientific Meeting Read more about Zafgen to Present at The Obesity Society 29th Annual Scientific Meeting Pagination First page « First Previous page ‹ Previous … Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Current page 23 Page 24 Page 25 Next page Next › Last page Last » Subscribe to
Zafgen, Inc. Announces Participation at XSITE 2009 Read more about Zafgen, Inc. Announces Participation at XSITE 2009
Zafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009 Read more about Zafgen, Inc. Named One of the “Fierce 15” Leading Biotech Companies of 2009
Zafgen, Inc. to Present at Upcoming Conferences Read more about Zafgen, Inc. to Present at Upcoming Conferences
Zafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting Read more about Zafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity Read more about Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
Zafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference Read more about Zafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference
Zafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting Read more about Zafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Zafgen Secures $33 Million Series C Financing Read more about Zafgen Secures $33 Million Series C Financing
Zafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer Read more about Zafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
Zafgen to Present at The Obesity Society 29th Annual Scientific Meeting Read more about Zafgen to Present at The Obesity Society 29th Annual Scientific Meeting